VIDEO: Patients with UC achieve symptomatic remission ‘as early as week 4’ with Tremfya

CHICAGO — In a Healio video exclusive, Jessica R. Allegretti, MD, MPH, explains that nearly 23% of patients with moderate to severe ulcerative colitis achieved clinical remission with Tremfya, compared with less than 10% on placebo.In a late-breaker presentation at Digestive Disease Week, Allegretti shared results from the QUASAR phase 3 induction study, which evaluated the efficacy and safety of Tremfya (guselkumab, Janssen Biotech) induction therapy in patients with moderately to severely active UC, who had an inadequate response or were intolerant to previous therapy.“GuselkumabRead More